While Cyclacel Pharmaceuticals Inc has overperformed by 1351230%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CYCC fell by -94.33%, with highs and lows ranging from $39.84 to $0.25, whereas the simple moving average fell by -95.12% in the last 200 days.
On July 18, 2022, Oppenheimer started tracking Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) recommending Outperform. H.C. Wainwright Initiated an Buy rating on October 16, 2015, and assigned a price target of $5. Roth Capital initiated its ‘Buy’ rating for CYCC, as published in its report on February 04, 2010. Piper Jaffray also rated the stock as ‘Buy’.
Analysis of Cyclacel Pharmaceuticals Inc (CYCC)
Investors in Cyclacel Pharmaceuticals Inc will get a return regardless of how the company performs over the next quarter since the company’s dividend stands at $2.40 per share. Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
One of the most important indicators of Cyclacel Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -1949.77% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CYCC is recording 1.33M average volume. On a monthly basis, the volatility of the stock is set at 23.85%, whereas on a weekly basis, it is put at 9.85%, with a loss of -5.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $16.00, showing decline from the present price of $1330000.0, which can serve as yet another indication of whether CYCC is worth investing in or should be passed over.
How Do You Analyze Cyclacel Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.00%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 0.46% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CYCC shares are owned by institutional investors to the tune of 0.46% at present.
